| 摘要 |
<p>The present invention provides for the pegylation of therapeutic antibodies to treat HCV infections. More specifically, the invention relates to site-specific pegylation of E2 antibody fragments at specifically defined amino acid residue(s) that is optionally engineered away from the antigen binding sites. The pegylated-MAb derivatives show substantially improved pharmacokinetic and pharmacodynamic properties, and they are broadly-neutralizing against several HCV clinical isolates by selectively binding to broadly-conserved neutralization epitope(s) of HCV E2 glycoprotein.</p> |
